SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is seeing a significant surge amid widespread rumors of an impending partnership with Novo Nordisk to sell obesity drugs on its platform, fueling intense short squeeze speculation due to high short interest and renewed optimism around its expanding peptide offerings.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following a surprise partnership with Hims & Hers to sell obesity drugs, a move the community views as trapping shorts and signaling a major turnaround. This development, coupled with rapidly accelerating adoption of its oral Wegovy and a recent FDA crackdown on compounded GLP-1s, has many calling the stock a generational buying opportunity despite past competitive pressures.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community celebrates the imminent departure of a prominent FDA official, widely seen as a significant barrier to the approval of its Duchenne Muscular Dystrophy therapy, Deramiocel. This development, coupled with high anticipation for a late-breaking Phase 3 data presentation at a major medical conference next week, is fueling intense bullish sentiment and expectations for a rapid regulatory decision.

Seeker is building a decentralized mobile ecosystem designed to challenge entrenched mobile incumbents through its TEEPin network architecture and community governance. It aims to solve the pain points of centralized app store gatekeeping, lack of developer freedom, and restricted user access to crypto applications. The vision is to create a community-owned platform with decentralized governance, no gatekeepers, direct developer-user access, and TEEPin security architecture.

Seeker

Seeker ($SKR) is gaining significant attention and volume following new listings on major exchanges, positioning it as the utility token for the Solana Mobile "Seeker" smartphone ecosystem. The community is actively discussing breaking key resistance levels with strong bullish conviction, though some caution about potential selling pressure from recent airdrops and staking unlocks.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group ($DJT) is trending amidst intense community discussion following the release of new Epstein files containing sexual assault allegations against Donald Trump, alongside widespread concern over the ongoing conflict with Iran and its perceived negative impact on the economy and gas prices.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is seeing immense upward pressure as escalating geopolitical tensions in the Middle East have effectively disrupted shipping through the critical Strait of Hormuz, causing widespread concerns about global oil supply. The community is actively discussing the potential for significantly higher crude prices, viewing the situation as a genuine supply 'plumbing break' rather than just a fleeting fear-driven rally.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF (DIA) is highly volatile amid escalating Middle East tensions driving oil prices higher and intensifying inflation concerns, leading the community to debate potential market downturns and Federal Reserve policy implications.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is trending as a recent AI licensing partnership in Africa sparks widespread discussion about a potential massive short squeeze, driven by a low float, increasing short interest, and extremely high borrow rates. The stock's ability to remain green amidst broader market volatility is also a key point of community excitement.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as the community anticipates a more permissive regulatory environment for its gene therapies following the imminent departure of a prominent FDA official, an event coupled with the CEO's announced retirement sparking M&A speculation and excitement for upcoming pivotal clinical data.

Rithm Capital Corp. engages in the provision of real estate, credit, and financial services. It operates through the following segments: Origination and Servicing, Investment Portfolio, Residential Transitional Lending, Asset Management, and Corporate. The Origination and Servicing segment includes residential mortgage loans underlying mortgage servicing right assets as well as those sub-service for third parties. The Investment Portfolio segment consists of residential mortgage loans, SFR properties, consumer loans, Non-Agency RMBS, Excess MSRs and servicer advance investments. The Residential Transitional Lending segment competes for both experienced sponsors, including developers and investors in residential real estate, and attractive lending opportunities based on several factors. The Asset Management segment focuses on the wholly owned subsidiaries, Sculptor, and RCM Manager. The company was founded on September 26, 2011 and is headquartered in New York, NY.

Rithm Capital Corporation

Anticipation of Rithm Capital's inclusion in the S&P SmallCap 600 is driving current interest, with the community highlighting expected "forced buying" from index funds. This is further fueled by discussions around the company's strong performance, recent strategic acquisitions, and the long-term potential of a C-Corp conversion to unlock its perceived undervaluation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Capricor Therapeutics (NASDAQ:CAPR) Trading Up 6.2% - Here's What Happened

Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 6.2% - Here's Why...

<ul class="summary-bullets"><li>Late-breaking Phase 3 results will be presented at the Muscular Dystrophy Association conference on March 11 in Orlando.</li><li>Regulatory review for Deramiocel is ongoing, with the FDA requesting the full Hope-3 clinical study report as part of its review.</li><li>The Hope-3 trial previously reported positive topline results, showing a slower decline in upper limb function and improved cardiac performance.</li></ul>Shares of Capricor Therapeutics, Inc. (CAPR)&nbsp;drew heightened retail buzz on Thursday as investors weighed the company’s upcoming reveal of Phase 3 Duchenne muscular dystrophy (DMD) data next week, which will highlight muscle and cardiac benefits from its cell therapy Deramiocel.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> posted its third straight day of losses in Wednesday’s regular session, slipping more than 1% to close at $25.5, though shares rebounded in extended trading, rising over 2% after-hours.<h2 class="st-heading-2">Hope-3 Trial Heads To MDA 2026</h2>Capricor said results from its Phase 3 Hope-3 study will be presented in a late-breaking oral session at the Muscular Dystrophy Association Clinical and Scientific Conference on March 11 in Florida, with national principal investigator Craig McDonald scheduled to present the data.DMD is a genetic disease that progressively weakens muscles and frequently leads to heart failure, making treatments that preserve both muscle and cardiac function particularly important.Capricor CEO Linda Marban said, “The selection of Hope-3 as a late-breaking presentation at the MDA Conference recognizes the strength and growing body of clinical evidence supporting Deramiocel and its potential impact for patients living with Duchenne.”<h2 class="st-heading-2">CAPR Moves Ahead In FDA Process</h2>The conference presentation comes as the therapy continues through the U.S. Food and Drug Administration (FDA) regulatory review. In January, Capricor said the FDA&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-rallied-this-week-february-fda-catalyst/cZRZMVdR4Dq">formally requested</a> the full clinical study report from the Hope-3 trial as part of the ongoing review of the company’s biologics license application for Deramiocel.The company said the report will address items outlined in a Complete Response Letter issued in July 2025. Capricor added that the submission allows the FDA to continue evaluating the therapy and could lead to the assignment of a new Prescription Drug User Fee Act (PDUFA) target action date.Notably, the FDA did not request any additional clinical trials or new patient data during the review.<h2 class="st-heading-2">Phase 3 Hope-3 Meets Primary Goal</h2>Capricor reported positive topline results from the Hope-3 study in December. The Phase 3 trial met its primary endpoint by demonstrating a statistically significant slowing in the decline of upper limb function in patients with Duchenne muscular dystrophy. The therapy also showed improvement in a key cardiac measure known as left ventricular ejection fraction.The study enrolled 106 boys and young men with Duchenne, including patients who can no longer walk. Capricor said the therapy demonstrated benefits across both skeletal muscle and cardiac outcomes while maintaining a safety profile consistent with earlier studies.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for CAPR was ‘bearish’ amid a nearly 50% jump in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/capr_ss_png_edc044a2fe.webp" alt="capr ss.png" width="965" height="142"><figcaption>CAPR sentiment and message volume as of March 5 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Schiellerup/message/646613834">noted</a> that the stock’s relatively small free float makes price swings more likely, adding that once news flow and trading volume increase, the situation could change quickly.<stembedurl>https://stocktwits.com/Schiellerup/message/646613834</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Gabriel_DS/message/646615261">said</a>, “CAPR is my only red today, and honestly, I don't even mind. I know it’ll take off again in no time, so it’s all good.”<stembedurl>https://stocktwits.com/Gabriel_DS/message/646615261</stembedurl>CAPR stock has declined 12% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains

The FDA review of Deramiocel remains ongoing and could eventually lead to the assignment of a new PDUFA decision date.

Equity

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Rating of "Moderate Buy" from Analysts

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten research firms that are covering the company, Marketbeat Ratings...

<ul class="summary-bullets"><li>Capricor is preparing a February submission to the FDA for its DMD cell therapy Deramiocel, following a formal request for the full Phase 3 Hope-3 clinical study report.</li><li>Koyfin expects Sarepta to post Q4 revenue of $390.95 million, and an EBITDA loss of $144.34 million.</li><li>Koyfin estimates call for no revenue, and an EBITDA loss of $24.60 million for Capricor.&nbsp;</li></ul>Shares of Capricor Therapeutics, Inc. (CAPR) and Sarepta Therapeutics, Inc. (SRPT) are in focus this week as investors weigh different near-term catalysts tied to Duchenne muscular dystrophy (DMD), a severe genetic disorder that causes progressive muscle degeneration and heart failure, primarily in young boys.Capricor is preparing a regulatory filing with the U.S. Food and Drug Administration (FDA) and is also set to report fourth-quarter (Q4) earnings this week, while Sarepta reports Q4 results amid safety and legal overhangs.<h2 class="st-heading-2">Capricor Prepares February FDA Submission For Deramiocel</h2>Capricor is positioning for a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-rallied-this-week-february-fda-catalyst/cZRZMVdR4Dq">February submission</a> to the FDA related to its cell therapy Deramiocel, following a formal request from the agency for the full clinical study report from the Phase 3 Hope-3 trial. The company said preparation of the report is “well underway” and that the submission is intended to address the issues raised in a Complete Response Letter issued in July 2025.Importantly, the FDA did not request any new clinical trials or additional patient data as part of the request. The Hope-3 trial enrolled 106 boys and young men with Duchenne muscular dystrophy, including patients who can no longer walk, and met its primary endpoint by showing a slowing in the decline of upper limb function.&nbsp;The study also demonstrated improvement in a key cardiac endpoint measuring left ventricular ejection fraction. Capricor said the safety profile was consistent with earlier studies.<h2 class="st-heading-2">Wall Street View On CAPR</h2>Capricor is scheduled to report quarterly results on Friday. According to Koyfin estimates, the company is expected to report no revenue for the quarter, with earnings before interest, taxes, depreciation, and amortization (EBITDA) projected at a loss of $24.60 million, compared with a loss of $25.79 million last quarter.&nbsp;Earnings before interest and taxes (EBIT) are expected at a loss of $25.87 million versus $26.28 million last quarter. Adjusted EPS is projected at a loss of $0.55, widening slightly from $0.54 in the previous quarter.Analyst sentiment around Capricor remains strongly following the Phase 3 data. Koyfin data show a 12-month average price target of $50.8, implying a 78% upside from the stock’s last close. Of the 10 analysts covering the stock, two rate it ‘Strong Buy’ and eight rate it ‘Buy.’<h2 class="st-heading-2">Sarepta Faces Earnings Amid Legal and Safety Overhangs</h2>Sarepta Therapeutics is due to report fourth-quarter (Q4) results after market close on Wednesday. The earnings release comes as the company continues to navigate regulatory scrutiny of its Duchenne gene therapy, Elevidys, and renewed legal uncertainty after the U.S. Court of Appeals for the Federal Circuit&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-hits-fresh-hurdle-as-court-revives-patent-lawsuit-with-regenxbio-over-muscular-disorder-therapy/cZRNSgQR4xu">reinstated</a> a patent lawsuit brought by Regenxbio.The lawsuit centers on claims that Elevidys infringes gene-therapy patents licensed from the University of Pennsylvania, with Regenxbio and Penn seeking more than $900 million in damages. Sarepta has also faced safety concerns after two patients who could not walk died from acute liver failure following Elevidys treatment in 2025. While shipments have resumed for ambulatory patients, the company is still developing a risk-mitigation strategy to resume use in non-ambulatory patients.<h2 class="st-heading-2">Wall Street View On SRPT</h2>Koyfin estimates show Sarepta is expected to report quarterly revenue of $390.95 million, down from $399.36 million in the prior quarter. EBITDA is projected to widen to a loss of $144.34 million from $91.17 million previously, while EBIT is expected at a loss of $136.41 million versus $103.39 million. Adjusted EPS is expected at a loss of $0.77 versus an earlier $0.13.Analyst sentiment on Sarepta is notably more mixed than on Capricor. Koyfin data shows a 12-month average price target of $21.43, implying a 14% upside from the stock’s current levels. Among 26 analysts covering the stock, seven rate it ‘Buy’, fourteen rate it ‘Hold’, three rate it ‘Sell’, and two rate it ‘Strong Sell’.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment toward Capricor was ‘extremely bullish’ amid ‘extremely high’ message volume, while sentiment toward Sarepta was ‘bearish’ amid ‘low’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/capr_ss_png_75fc2bd5be.webp" alt="capr ss.png" width="969" height="142"><figcaption>CAPR sentiment and message volume as of February 23 | Source: Stocktwits</figcaption></figure><figure class="image"><img src="https://news.stocktwits-cdn.com/srpt_ss_png_ee5b558d89.webp" alt="srpt ss.png" width="969" height="144"><figcaption>SRPT sentiment and message volume as of February 23 | Source: Stocktwits</figcaption></figure>One user said they were “patiently waiting for the Roche buyout” of Capricor.&nbsp;<stembedurl>https://stocktwits.com/txasholdem/message/645533286</stembedurl>Another user said, “Serapta can make much safer one for DMD. We will see the development very soon!”<stembedurl>https://stocktwits.com/Alzdoc/message/645520324</stembedurl>While CAPR stock has declined 1.2% year-to-date, SRPT stock slid 12% over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside?

Capricor is approaching a regulatory filing timeline and earnings, while Sarepta heads into results under legal and safety pressure.

<ul class="summary-bullets"><li>President Donald Trump announced over the weekend that global tariffs would rise from 10% to 15%.&nbsp;</li><li>Traders are also watching last-ditch nuclear negotiations with Iran scheduled in Geneva later this week.&nbsp;</li><li>Nvidia earnings later this week could define the next leg of the market.</li></ul>U.S. stock futures were sharply lower early Monday as investors grappled with a renewed tariff uncertainty, rising geopolitical tensions with Iran, and awaited Nvidia's big earnings report later this week. Last week’s momentum is being tested by President Donald Trump’s announcement over the weekend of a hike in global tariffs from 10% to 15%, which came a day after the Supreme Court struck it down as ‘anti-American.’The markets are also watching last-ditch nuclear talk attempts with Iran in Geneva this Thursday, amidst reports that the U.S. is considering significant military action if diplomacy fails.&nbsp;As of 3:00 a.m. ET on Monday, Nasdaq futures fell 0.6%, the S&amp;P 500 and Dow futures declined 0.5%, while Russell 2000 futures were down nearly 1%.Meanwhile, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, has moved to ‘bearish’ from ‘neutral’ last week, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has remained ‘bearish’ amid high message volumes.&nbsp;On the other hand, precious metals have seen a breakout, with gold rising above $5,100 and silver nearing $88/oz.&nbsp;Trending Stocks To WatchNvidia (NVDA):&nbsp;The chip giant reports earnings on Feb 25. Beyond its guidance, all eyes will be on its commentary on AI hype, investments, and sustainability.Netflix (NFLX):&nbsp;The stock is facing potential downward pressure after President Trump threatened consequences if board member Susan Rice is not removed. This adds another layer of uncertainty as it pursues its bid for Paramount Skydance (PSKY).&nbsp;Honeywell (HON):&nbsp;It has entered into an amended deal to acquire Johnson Matthey’s Catalyst Technologies business for $1.8 billion.Vanda Pharmaceuticals (VNDA):&nbsp;The US FDA has approved Bysanti for bipolar I disorder and schizophrenia.Moonlake Immunotherapeutics (MLTX):&nbsp;Positive Phase 2 data for its spinal disease drug have led to strong after-hours gains. Traders will be watching this stock closely as we head into a new week.&nbsp;Immunity Bio (IBRX):&nbsp;This biotech stock continues to garner retail attention. Executive chairman Patrick Soon-Shiong&nbsp;<a href="http://stocktwits.com/news-articles/markets/equity/ibrx-stock-open-week-on-high-chairman-teases-anktiva-3-year-expansion-plans-cancer-breakthrough/cZRtSeQR4Us">teased</a> a detailed three-year expansion roadmap, with a detailed press release expected on Monday.&nbsp;Deere &amp; Co (DE):&nbsp;One of the most actively traded stocks last week saw a downgrade to ‘Underperform’ from Jefferies, with a target price of $550. The analyst believes it is already ‘discounted a full recovery’ and trades at steep valuations.&nbsp;Rolls-Royce (RYCEY): The company is reportedly preparing a buyback program of up to €1.5 billion.Other tickers trending on Stocktwits at the time of writing included Capricor Therapeutics (CAPR), Kraft Heinz Co (KHC), Oklo Inc (OKLO), and Ardelyx (ARDX), among others.&nbsp;Other Catalysts To WatchOn the economic front, investors will be monitoring the release of factory orders at 10:00 am ET. They will also be watching for commentary from Fed Governor Christopher Wallace before the bell today.&nbsp;On the earnings radar, investors will be watching for the quarterly reports from Domino’s Pizza (DPZ), GeneDX (WGS), Freshpet (FRPT), and Dominion Energy (D), among others, before the bell&nbsp;today. Also watch out for Hims &amp; Hers (HIMS), Keysite Technologies (KEYS), and Diamonback Energy (FANG) that report after market close.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today

Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’. 

<ul class="summary-bullets"><li>The February filing centers on Deramiocel’s Phase 3 Hope-3 data, following the FDA's request for the full clinical study report without requiring new trials.</li><li>The company's Phase 3 results showed skeletal muscle and heart-related benefits for patients with DMD.</li><li>Capricor said the submission will address the items raised in a Complete Response Letter it received in July 2025.</li></ul>Shares of Capricor Therapeutics, Inc. (CAPR) have surged nearly 30% this week as investors position themselves ahead of a key February FDA filing that could move its Duchenne Muscular Dystrophy (DMD) therapy closer to approval.On Thursday,&nbsp;<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> jumped over 14% to its highest level and strongest session since December, when the company reported its DMD therapy met its Phase 3 primary endpoint.<h2 class="st-heading-2">February FDA Step In Focus</h2>In January, Capricor said the U.S. Food and Drug Administration (FDA) formally requested the full clinical study report from its Phase 3 Hope-3 trial as part of the ongoing review of the company’s application to market Deramiocel.Deramiocel is the drugmaker’s cell therapy that preserves skeletal muscle and heart function in patients with DMD, a genetic disorder that progressively weakens muscles and often leads to heart failure.The company had said that preparation of the Hope-3 report is “well underway” and that it plans to submit the requested materials in February. Capricor said the submission will address the items raised in a Complete Response Letter it received in July 2025 and allow the FDA to continue its review, including setting a new target decision date.Notably, the FDA did not ask for any new clinical trials or additional patient data as part of the request.<h2 class="st-heading-2">What Hope-3 Showed</h2>The February submission comes on the heels of positive topline data Capricor reported in December from its Phase 3 Hope-3 trial. The study met its primary endpoint, showing a statistically significant slowing of the decline in upper limb function, and also demonstrated improvement on a key cardiac endpoint measuring left ventricular ejection fraction.The trial enrolled 106 boys and young men with DMD, including people who cannot walk, and showed both skeletal muscle and heart-related benefits. Capricor said the therapy maintained a safety profile consistent with earlier studies.<h2 class="st-heading-2">Analysts Turn More Bullish</h2>Following the Hope-3 readout and regulatory update, several Wall Street firms raised price targets and reiterated positive ratings on Capricor shares.B. Riley lifted its price target to ‘$50’ from ‘$21’ and maintained a ‘Buy’ rating, citing a higher probability of approval based on “statistically significant and clinically meaningful data.” The firm said its updated assumptions reflect a 75% probability of success and risk-adjusted sales&nbsp;exceeding $1 billion by 2030.Piper Sandler raised its target to ‘$45’ from ‘$20’ and kept an ‘Overweight’ rating, saying the Hope-3 data support a potential approval timeline as early as mid-2026 following a standard review.Oppenheimer boosted its target to ‘$54’ from ‘$22’ with an ‘Outperform’ rating, arguing Deramiocel’s clinical profile compares favorably with existing Duchenne therapies and said its projected 2031 sales of about $1.1 billion in the U.S. alone through partner NS Pharma may prove “conservative.”Other brokerages, including H.C. Wainwright, Maxim, and Alliance Global, also raised targets to the $48-$60 range while maintaining ‘Buy’ ratings following the Phase 3 results.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for CAPR was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/capr_ss_png_74e3ddf28e.webp" alt="capr ss.png" width="969" height="144"><figcaption>CAPR sentiment and message volume as of February 19 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Notquiteabillionaire/message/645385777">said</a>, “Tomorrow looking to be a very interesting Friday indeed. Last two days don't suggest a profit taking sell-off, this was a structurally solid two days.”<stembedurl>https://stocktwits.com/Notquiteabillionaire/message/645385777</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Stonksgoingup/message/645403730">said</a> that a BLA resubmission could eventually lead to FDA approval and, if the drug reaches the market, longs will be rewarded with upside benefits.&nbsp;<stembedurl>https://stocktwits.com/Stonksgoingup/message/645403730</stembedurl>CAPR stock has risen 1% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CAPR Stock Rallied Nearly 30% So Far This Week — Here’s The February FDA Catalyst Investors Are Betting On

Shares jumped over 14% on Thursday to their highest level and strongest session since December, when the company reported strong DMD trial results.

Capricor Therapeutics (NASDAQ:CAPR) Trading 12.2% Higher - Time to Buy?

Capricor Therapeutics (NASDAQ:CAPR) Shares Up 12.2% - What's Next...

GSA Capital Partners LLP Makes New $1.56 Million Investment in Capricor Therapeutics, Inc. $CAPR

GSA Capital Partners LLP purchased a new stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) in the third quarter, according to the company in its most recent filing with the Securities...

Capricor Therapeutics (NASDAQ:CAPR) Shares Cross Above 50-Day Moving Average - Time to Sell?

Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above Fifty Day Moving Average - Time to Sell...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the ten ratings firms that are covering the firm, Marketbeat...

Up 5%+

Up 0–5%

Down 0–5%

Down 5%+

Stocktwits

Stocktwits Polls

Traders are ecstatic about the departure of a controversial FDA official, widely believed to clear the path for key drug approvals.

Users predict significant gains with targets of "$40+" and "triple digits," fueling expectations for a massive short squeeze as bears scramble to cover positions.

Upcoming presentation of strong Phase 3 data at the MDA conference on March 11th heightens expectations for expedited FDA approval for the Duchenne Muscular Dystrophy treatment.

CAPR
Capricor Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CAPR News

CAPRCapricor Therapeutics Inc